Want to join the conversation?
Specialty generic pharmaceutical company $AKRX reported higher 1Q16 results, helped in part by portfolio growth, and maintained its 2016 outlook. The company reported 1Q16 earnings of $42MM, or $0.34 per share, compared to $38MM, or $0.31 per share a year ago. Revenue rose 18% to $268MM.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.